DOCSLIB.ORG

AUTHOR INDEX December 1980 Abeloff, MD

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
AUTHOR INDEX December 1980 Abeloff, MD AUTHOR INDEX December 1980 Abeloff, M. D., 4420 Garson, O. M., 4826 Leserman, L. D., 4768 Russell, D. H., 4373 Abrams, P. G., 4356 Gazdar, A. F., 4356 Levitt, D. S., 4456 Adler, K. B., 4403 George, R., 4717 Levy, J. A., 4364 Sakurai, M., 4826 Aldenderfer, P., 4420 Gérard,G. F., 4398 U, G. C., 4501 Saladik, D., 4433 Alimena, G., 4826 Oilman, S. C., 4640 Loewenstein, P. M., 4398 Sandberg, A. A., 4512, 4826 Amin, S., 4528 Giuliani, F. C., 4682 Lyon, l., 4606 Sanford, K. K., 4415 Anderson, C., 4519 Gold, A., 4482 Sasaki, K., 4810 Anderson, S. N., 4571 Goldenberg, G. J., 4489 Maclntyre, l., 4764 Sasaki, M. S., 4796 Goldfarb, S., 4717 Maekawa, T., 4813 Sattler, C. A., 4552 Andrews, J. P., 4688 Mak, W. W-N., 4552 Arafah, B. M., 4628 Golomb, H. M., 4826 Shimano, T., 4658 Gordon, C., 4546 Manabe, H., 4791 Shrivastav, S., 4438, 4443 Bachur, N. R., 4669 Gordon, R. E., 4467 Manni, A., 4628 Simms, E., 4356 Bainton, D. F., 4473 Graham, D., 4482 Martin, T. J., 4764 Skipper, P. L., 4704 Baker, M. H., 4734 Grayhack, J. T., 4524 Mashiba, H., 4791 Smith, G. L, 4368 Matsui, S-i., 4512 Baker, N., 4606 Greco, W. R., 4617 Smith, l. E., 4734 Banerjee, M. R., 4368 Greenberg, P. D., 4428 Matsumoto, K., 4781 Smyth, J. F., 4734 Barthold, S. W., 4451 Grier, A. H.,441 5 Matsushima, T., 4775 Sokal, G., 4826 Meade-Cobun, K. S., 4519 Bech, D.,4451 Groopman, J. D., 4343 Somer, K. D., 4410 Bedenke, V., 4528 Grover, J., 4489 Memoli, V. A., 4571 Sorof, S., 4688 Begleiter, A., 4489 Cullino, P. M., 4628 Meyer, L. W., 4599 Speck, W. T., 4599 Bhatt, R. S., 4581 Michelangeli, V. P., 4764 Stanley, J. R., 4694 Bialkowski, S., 4617 Haglund, U., 4786 Minna, J. D., 4356 Sternberg, S. S., 4546 Bishop, W. W., 4704 Hahn, G. M., 4501 Mitelman, F., 4826 Stone, K. R., 4438, 4443 Blackburn, G. R., 4688 Hawley-Nelson, P., 4694 Miura, T., 4813 Sun, A. S., 4677 Blumer, J. L., 4599 Hayata, I., 4781 Miyamoto, K., 4751 Bonar, R. A., 4438, 4443 Hayder, S., 4786 Mokyr, M. B., 4565 Takahashi, K., 4775 Boreiko, C., 4709 Hecht, S. S., 4528 Mondai, S., 4709 Takahashi, M., 4810 Borgström, G. H., 4826 Heidelberger, C., 4581, 4709 Moore, J. J., 4768 Takenaka, K., 4791 Boynton, A. L., 4541 Hellman, S., 4335 Moore, M., 4482 Tan, C., 4546 Brandt, L., 4826 Henneberry, M. O., 4524 Moseley, J. M., 4764 Tannenbaum, S. R., 4704 Bryant, B. M., 4734 Herbst, A. L., 4612 Mossman, B. T., 4403 Tarone, R. E., 4415 Bugelski, P., 4460 Hess, A. D., 4495 Muller-Eberhard, U., 4456 Telfer, N., 4581 Busby, W. F., Jr., 4343 Hoffmann, D., 4528 Murphy, G. P., 4658 Terasaki, T., 4751 Hoffman, H. A., 4415 Murphey, M. M., 4410 Terry, W. D., 4768 Cabrai, J. R. P., 4739 Horaguchi, K., 4775 Thilly, W. G., 4704 Calderwood, S. K., 4728 Hosick, H. L., 4631 Naganuma, K., 4758 Thorgeirsson, S. S., 4456 Catovsky, D., 4826 Hossfeld, D. K., 4826 IMarayan, K. S., 4709 Todaro, G. J., 4722 Cederbaum, A. l., 4677 Howard, B., 4482 Narita, N., 4781 Tohda, H., 4775 Check, l. J., 4612 Howard, E. F., 4385 Nayar, K. T., 4364 Tomida, M., 4804 Cheever, M. A., 4428 Howard, J. S., 4385 Neal, G. E., 4739 Tompkins, W. A. F., 4744 Cheng, C. Y., 4385 Hozumi, M., 4804 Nelson, J. A., 4381 Topping, D. C., 4352 Chou, T-C., 4546 Hreshchyshyn, M. M., 4512 Nesnow, S., 4482 Tsukagoshi, S., 4758 Chu, T. M., 4658 Hunter, R. L, 4612 Nettesheim, P., 4352 Tsunematsu, Y., 4796 Clarke, A. A., 4640 Husby, G., 4648 Nishiura, T., 4658 Tsuruo, T., 4758 Clawson, R. E., 4669 Nogiwa, E., 4813 Tung, K. S. K., 4648 lida, H., 4758 Cohen, J. L., 4669 Nomura, Y., 4791 Tyagi, A. K., 4390 Iribe, H., 4791 Cooney, D. A., 4390 O'Brien, T. G., 4433 Craighead, J. E., 4403 Iyer, A. P., 4368 Uchida, N., 4781 Craven, P. A., 4589 lype, P. T., 4663 Oikawa, A., 4775 Utsumi, J., 4796 Curtis, G., 4482 Okamoto, S., 4781 Utsunomiya, J., 4796 Jarman, M., 4734 Oison, J. W., 4373 O'Neill, B., 4364 Danielson, K. G., 4631 Johnson, E. F., 4456 Valenzuela, L., 4658 Dave, S., 4617 Jones, G. M., 4415 Oyasu, R., 4524 van den Berghe, H.. 4826 Dawson, J. R., 4495 van Orshoven, A., 4826 de la Chapelle, A., 4826 Kaku, M., 4791 Papsidero, L. D., 4658 Verwilghen, R., 4826 DeRubertis, F. R., 4589 Kannan, R., 4606 Parshad, R., 4415 Vuopio, P., 4826 Dewald, G. W., 4826 Kaplan, N. O., 4682 Pauli, B. U., 4571 Dickson, J. A., 4728 Kaszubowski, P. A., 4648 Paulson, D. F., 4438, 4443 Waalkes, T. P., 4420 Kelly, E., 4533 Pavelic, Z. P., 4617 Wake, N., 4512 Dittman, W. A., 4473 Keski-Oja, J., 4722 Docherty, J. J., 4640 Pearson, O. H., 4628 Wang, M. C., 4658 Dowdle, E. B., 4817 Killian, C. S., 4658 Philips, F. S., 4546 Warrell, R. P., Jr., 4546 Dray, S., 4565 Kirsh, R., 4460 Pierre, R. V., 4826 Webster, L. T., Jr., 4599 Kitamura, Y., 4781 Pitot, H. C., 4552 Weigent, D. A., 4381 Egorin, M. J., 4669 Knauer, D. J., 4368 Piver, S. M., 4512 Weinstein, J. N., 4768 Eisenstadt, E., 4482 Koehler, B., 4694 Pleshkewych, A., 4533 Whitehead, R., 4764 Eisman, J. A., 4764 Kouri, R. E., 4364 Pontzer, C. H., 4663 Whitfield, J. F., 4541 Ettinger, D. S., 4420 Krahenbuhl, J. L., 4622 Porter, C. W., 4533 Williams, R. C., Jr., 4648 Ezerman, E. B., 4403 Kramer, D. L., 4533 Poste, G., 4460 Wilson, E. L., 4817 Kramer, R. J., 4473 Priore, R. L., 4617 Wogan, G. N., 4343 Fairchild, E., 4599 Kruuv, J., 4485 Pzepiorka, D., 4565 Woo, K. B., 4420 Fefer, A., 4428 Kuettner, K. E., 4571 Feinberg, A., 4446 Kurashige, S., 4813 Rao, K. V. K., 4688 Yagawa, K., 4791 Fidler, l. J., 4460 Kuriyama, M., 4658 Rawls, W. E., 4640, 4744 Yamagata, J., 4791 Findlay, D. M., 4764 Kyriazis, A. A., 4509 Raz, A., 4460 Yamaguchi, K., 4781 Fogler, W. E., 4460 Kyriazis, A. P., 4509 Roberts, J., 4546 Yamamoto, Y., 4804 Romic-Stojkovic, R., 4821 Frampton, R. J., 4764 Yasumoto, K., 4791 Friedman, A., 4599 Landolph, J. R., 4581 Rosenberg, K. D., 4612 Young, C. W., 4546 Furth, E. E., 4704 Lane, B. P., 4467 Rosenthal, K. L., 4744 Yuspa, S. H., 4694 Lange, G. W., 4398 Ross, L. A., 4669 Gall, S. A., 4495 LaVoie, E. J., 4528 Rowland, R. G., 4524 Zamora, P. O., 4631 Gamulin, S., 4821 Lawler, S. D., 4826 Rowley, J. D., 4826 Zech, L., 4786 Garland, H., 4482 Lepock, J. R., 4485 Ruddon, R. W., 4420, 4519 Zedeck, M. S., 4446 DECEMBER 1980 4837 [CANCER RESEARCH 40, 4839-4868. December 1980] Index to Volume 40 Author Index 834; Weeks, Allaben, Tresp, Louie, Lazear, and Pearson, O. H. Effect of Ovariectomy on Hor King, 1204 mone Receptors and Growth of W-Nitrosometh- Abdelfattah-Gad, M. See Denk, Abdelfattah-Gad, Allegra, J. C. See DeWys, Allegra, Simon, and ylurea-induced Mammary Tumors in the Rat, Eckerstorfer, and Talcott, 2568 Lippman, 2423 4628 Ab«,S., and Sandberg, A. A. Sister Chromatid Allen, L. M., and Thornthwaite, J. T. Studies on Arakawa, M. See Fukuda, Shindo, Shimizu, Ar- Exchange and Growth Kinetics of Marrow Cells the Pharmacology and Cytokinetics of 1H-lm- akawa, and Mizuhira. 133 in Aneuploid Acute Nonlymphocytic Leukemias, adazo[1,2-b]pyrazolo (NSC-51143) with P815 Araki, E. See Gasa. Makita, Kameya, Kodama, 1292 Mastocytoma Cells, 4059 Araki, Yoneyama, Hirama, and Hashimoto, Abeloff, M. D. See Baylin, Abeloff, Goodwin, Car Allen, P. T. See Strickland, Saviolakis, Weislow, 3804 ney, and Gazdar, 1990; Waalkes, Abeloff, Woo, Allen, Hellman, and Fowler, 3570 Archibald, L. See Adams, Archibald, and Sey Ettinger, Ruddon, and Aldenderfer, 4420 Allfrey, V. G. See Boffa, Diwan, Grass, and Allfrey, mour-Munn, 3815 Abrams, P. G. See Simms, Gazdar, Abrams, and 1774 Ardalan, B., Cooney, D. A., Jayaram, H. N., Car- Minna, 4356 Alpert, E. See Kim, DeLand, Nelson, Bennett, rico, C. K., Glazer, R. l., Macdonald, J., and Accolla, R. S. See Carrel, Accolla. Carmagnola, Simmons, Alpert, and Goldenberg, 3008' Schein, P. S. Mechanisms of Sensitivity and and Mach, 2523 Althouse, R., Huff, J., Tomatis, L., and Wilbourn, Resistance of Murine Tumors to 5-Fluorouracil, Acs, G. See Mendelsohn, Gilbert, Christman, and J. An Evaluation of Chemicals and Industrial 1431 Acs, 1469; Mendelsohn, Michl, Gilbert, Acs, Processes Associated with Cancer in Humans Arlett, C. F., and Harcourt, S. A. Survey of Radi- and Christman, 3206 Based on Human and Animal Data: IARC Mon osensitivity in a Variety of Human Cell Strains, Adams, J. B. See Pewnim, Adams, and Ho, 1360 ographs Volumes 1 to 20, page 1 926 Adams, J. B., Archibald, L., and Seymour-Munn, Altman, A. See Von Hoff, Casper, Bradley, Trent, Arlin, Z. A., Sklaroff, R. B., Gee, T. S., Kempin, K. Dehydroepiandrosterone and Androst-5-ene- Hodach, Reichert, Makuch, and Altman, 3591 S. J., Howard, J., Clarkson, B. D., and Young, 3/J,17/?-diol in Human Mammary Cancer Cytc- Altman, N. H. See Radomski, Deichmann, Altman, C. W. Phase I and II Trial of 4'-(9-Acridinyla- solic and Nuclear Compartments and Their Re and Radomski, 3537 mino)methanesulfon-m-anisidide in Patients lationship to Estrogen Receptor, 3815 Amare, M. See Park, Amare, Savin, and Hoogs- with Acute Leukemia, 3304 Adams, L. M. See Kennel. Lankford, Foote, Tsak- traten, 1062 Armbrecht, H. J. See Zenser, Mattammal, Arm eres. Adams, and Ullrich.
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2019 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr
    US008158152B2 (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr. 17, 2012 (54) LYOPHILIZATION PROCESS AND 6,884,422 B1 4/2005 Liu et al. PRODUCTS OBTANED THEREBY 6,900, 184 B2 5/2005 Cohen et al. 2002fOO 10357 A1 1/2002 Stogniew etal. 2002/009 1270 A1 7, 2002 Wu et al. (75) Inventor: Nageswara R. Palepu. Mill Creek, WA 2002/0143038 A1 10/2002 Bandyopadhyay et al. (US) 2002fO155097 A1 10, 2002 Te 2003, OO68416 A1 4/2003 Burgess et al. 2003/0077321 A1 4/2003 Kiel et al. (73) Assignee: SciDose LLC, Amherst, MA (US) 2003, OO82236 A1 5/2003 Mathiowitz et al. 2003/0096378 A1 5/2003 Qiu et al. (*) Notice: Subject to any disclaimer, the term of this 2003/OO96797 A1 5/2003 Stogniew et al. patent is extended or adjusted under 35 2003.01.1331.6 A1 6/2003 Kaisheva et al. U.S.C. 154(b) by 1560 days. 2003. O191157 A1 10, 2003 Doen 2003/0202978 A1 10, 2003 Maa et al. 2003/0211042 A1 11/2003 Evans (21) Appl. No.: 11/282,507 2003/0229027 A1 12/2003 Eissens et al. 2004.0005351 A1 1/2004 Kwon (22) Filed: Nov. 18, 2005 2004/0042971 A1 3/2004 Truong-Le et al. 2004/0042972 A1 3/2004 Truong-Le et al. (65) Prior Publication Data 2004.0043042 A1 3/2004 Johnson et al. 2004/OO57927 A1 3/2004 Warne et al. US 2007/O116729 A1 May 24, 2007 2004, OO63792 A1 4/2004 Khera et al.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev
    Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM GADOCOLETICUM 280776-87-6 ABAFUNGIN 129639-79-8 ACIDUM LIDADRONICUM 63132-38-7 ABAMECTIN 65195-55-3 ACIDUM SALCAPROZICUM 183990-46-7 ABANOQUIL 90402-40-7 ACIDUM SALCLOBUZICUM 387825-03-8 ABAPERIDONUM 183849-43-6 ACIFRAN 72420-38-3 ABARELIX 183552-38-7 ACIPIMOX 51037-30-0 ABATACEPTUM 332348-12-6 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABETIMUSUM 167362-48-3 ACIVICIN 42228-92-2 ABIRATERONE 154229-19-3 ACLANTATE 39633-62-0 ABITESARTAN 137882-98-5 ACLARUBICIN 57576-44-0 ABLUKAST 96566-25-5 ACLATONIUM NAPADISILATE 55077-30-0 ABRINEURINUM 178535-93-8 ACODAZOLE 79152-85-5 ABUNIDAZOLE 91017-58-2 ACOLBIFENUM 182167-02-8 ACADESINE 2627-69-2 ACONIAZIDE 13410-86-1 ACAMPROSATE
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Inhibition of Prolactin-Induced Mammary Cancer in C3hf (XVII) Mice with the Frans Isomer of Bromotriphenylethylene1
    [CANCER RESEARCH 40, 1674-1679, May 1980] 0008-5472/80/0040-OOOOS02.00 Inhibition of Prolactin-induced Mammary Cancer in C3Hf (XVII) Mice with the frans Isomer of Bromotriphenylethylene1 Michel Drosdowsky, Marc Edery,2 Michèle Guggiari, America Montes-Rendon, Georges Rudali, and Claude Vives Laboratoire de Biochimie, Centre Hospitalier et Universitaire de Caen. Côte de Nacre. 14040 Caen ¡M.D.. M. E.¡.and Equipe de Recherches 190 du Centre National de la Recherche Scientifique. Fondation Curie, 26. rue d Ulm. 75005 Paris. France ¡M.G.. A. M-R.. G. R., C. V.¡ ABSTRACT under the kidney capsule, 90% presented such cancers (33). It was shown recently in life span experiments that a brominated C3Hf (XVII) mice never develop spontaneous mammary tu triphenylethylene, commonly known as broparestrol, adminis mors. However, the transplantation of an isologous pituitary tered to pituitary-transplanted young C3Hf (XVII) females, in gland under their kidney capsule is followed by a 10-fold hibits the development of mammary glands (22) and of mam increase in serum and pituitary prolactin content (180 ng/ml mary carcinogenesis (33). Broparestrol presents 2 isomer and 20 /ng/mg of tissue, respectively), concomitant with an forms like clomiphene, another derivative of triphenylethylene, increase of prolactin receptors in mammary glands. Under of which both isomers have been reported to produce different these conditions, mammary tumors appear in 90% of the mice. reactions in experimental animals (15, 16). Accordingly, we If a racemic brominated triphenylethylene, i.e., broparestrol, decided that it would be interesting to study separately the is administered, serum and pituitary prolactin decrease rapidly biological activities of the frans and the c/s forms (Chart 1).
    [Show full text]
  • Pharmaceuticals Appendix
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Council of Europe Committee of Ministers (Partial
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (82) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 2 June 1982 at the 348th meeting of the Ministers' Deputies and superseding Resolution AP (77) 1) AND APPENDIX containing the list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 31 October 1982 RESOLUTION AP (82) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION 1 (Adopted by the Committee of Ministers on 2 June 1982 at the 348th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands, the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969 and 5 May 1964, respectively, Considering that, under the terms of its Statute, the aim of the Council of Europe is to achieve a greater unity between its Members for the purpose of safeguarding and realising the ideals and principles which are their common heritage and facilitating their economic and social progress; Having regard to the
    [Show full text]